Can a simple drug make top surgery safer? new trial investigates
NCT ID NCT05794321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving tranexamic acid (TXA) through an IV during gender affirming mastectomy (top surgery) can reduce complications like hematoma (blood collection) and seroma (fluid collection). 150 adults undergoing top surgery at UCSF will be randomly assigned to receive TXA or not. Researchers will track bleeding, drain output, and recovery time to see if TXA improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tranexamic acid (TXA)
- What this could lead to
- If it works, this could reduce complications like bleeding and fluid buildup after gender affirming mastectomy, leading to faster recovery.
- What could go wrong
- This is a small, early phase 2 trial. TXA may not reduce complications and carries a small risk of blood clots. Results may not apply to all surgery centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE HEMATOMA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSF Department of Plastic & Reconstructive Surgery
RECRUITINGSan Francisco, California, 94131, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.